Want to join the conversation?
$LLY said it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.